Insights into the Global Liver Disease Treatment Market to 2027 – By Treatment Type, Disease Type, End-User and Region | News

DUBLIN, April 12, 2022 /PRNewswire/ — The “Liver Disease Treatment Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027” report has been added to ResearchAndMarkets.comit is offer.

Global liver disease treatment market reached a value of US$20.83 billion in 2021. Looking ahead, the publisher expects the market to reach a value of US$30.91 billion by 2027 presenting a CAGR 6.50% over the 2022-2027 period. Keeping in mind the uncertainties of COVID-19, we continuously monitor and assess the direct and indirect influence of the pandemic. This information is included in the report as a major market contributor.

The liver is a vital organ in the human body that performs important functions, such as storing vitamins and nutrients, removing harmful substances from the blood, and maintaining the proper balance of chemicals in the body. Cancer, hepatitis, autoimmune diseases and genetic disorders are common liver diseases. These diseases are usually caused by infections, genetics, obesity, diabetes and immune system abnormalities. Some of the widely used therapeutic techniques for liver diseases include vaccines, chemotherapy, antiviral drugs, immunoglobulins, corticosteroids, and immunosuppressants. The treatment of liver disease helps in the excretion of cholesterol and hormones, increases the production of bile and the activation of enzymes.

Liver Disease Treatment Market Trends:

The growing geriatric population, which is susceptible to various chronic diseases including liver diseases, across the globe is one of the major factors driving the growth of the market. Changing dietary habits and sedentary lifestyles are driving the growth of the market.

Additionally, the growing prevalence of fatty liver due to high cholesterol, obesity, hypertension (high blood pressure), and diabetes is driving the growth of the market. Moreover, various technological advancements, such as the development of bioartificial liver, are providing impetus for the growth of the market. It uses regenerated liver cells to replace liver functions and is widely used for patients with acute liver failure.

With this in mind, the rapid adoption of antiviral drugs, because they are safe and effective, help suppress the hepatitis B virus and help reduce the risk of developing cirrhosis and hepatocellular carcinoma, has a positive impact on the market growth. Apart from this, increasing research and development (R&D) activities, significant growth in the healthcare sector, and implementation of various government initiatives to promote public health are creating a positive outlook for the market.

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the major players being Abbott Laboratories, AbbVie Inc., Astellas Pharma Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Emergent BioSolutions Inc., F. Hoffmann -La Roche AG, Gilead Sciences Inc., GlaxoSmithKline plc, Merck & Co. Inc., Novartis AG, Pfizer Inc., Sanofi SA, Takeda Pharmaceutical Company Limited and Viatris Inc.

Answers to key questions in this report:

• How has the global liver disease treatment market performed so far and how will it perform in the coming years?
• What has been the impact of COVID-19 on the global liver disease treatment market?
• What are the main regional markets?
• What is the market breakdown by type of treatment?
• What is the market breakdown by disease type?
• What is the market breakdown by end user?
• What are the different stages of the industry value chain?
• What are the key drivers and challenges in the industry?
• What is the structure of the global liver disease treatment market and who are the key players?
• How competitive is the industry?

Main topics covered:

1 Preface

2 Scope and methodology

3 Executive Summary

4 Presentation

4.1 Overview

4.2 Key Industry Trends

5 Global Liver Disease Treatment Market

5.1 Market Overview

5.2 Market Performance

5.3 Impact of COVID-19

5.4 Market Forecast

6 Market Breakdown by Treatment Type

6.1 Antiviral drugs

6.1.1 Market trends

6.1.2 Market Forecast

6.2 Immunosuppressants

6.2.1 Market trends

6.2.2 Market Forecast

6.3 Vaccines

6.3.1 Market trends

6.3.2 Market Forecast

6.4 Immunoglobulins

6.4.1 Market trends

6.4.2 Market Forecast

6.5 Corticosteroids

6.5.1 Market trends

6.5.2 Market Forecast

6.6 Targeted therapy

6.6.1 Market trends

6.6.2 Market Forecast

6.7 Chemotherapy

6.7.1 Market trends

6.7.2 Market Forecast

7 Market Breakdown by Disease Type

7.1 Hepatitis

7.1.1 Market trends

7.1.2 Market Forecast

7.2 Autoimmune diseases

7.2.1 Market trends

7.2.2 Market Forecast

7.3 Non-alcoholic fatty liver disease (NAFLD)

7.3.1 Market trends

7.3.2 Market Forecast

7.4 Cancer

7.4.1 Market trends

7.4.2 Market Forecast

7.5 Genetic disorders

7.5.1 Market trends

7.5.2 Market Forecast

7.6 Others

7.6.1 Market trends

7.6.2 Market Forecast

8 Market Breakdown by End User

8.1 Hospitals

8.1.1 Market trends

8.1.2 Market Forecast

8.2 Ambulatory surgery centers

8.2.1 Market trends

8.2.2 Market Forecast

8.3 Others

8.3.1 Market trends

8.3.2 Market Forecast

9 Market Breakdown by Region

10 SWOT Analysis

11 Value chain analysis

12 Analysis of the five forces of carriers

13 Price Analysis

14 Competitive landscape

14.1 Market structure

14.2 Major Players

14.3 Profiles of Key Players

14.3.1 Abbott Laboratories

14.3.1.1 Company Overview

14.3.1.2 Product portfolio

14.3.1.3 Finance

14.3.1.4 SWOT Analysis

14.3.2 AbbVie Inc.

14.3.2.1 Presentation of the company

14.3.2.2 Product portfolio

14.3.2.3 Finance

14.3.2.4 SWOT Analysis

14.3.3 Astellas Pharma Inc.

14.3.3.1 Company Overview

14.3.3.2 Product Portfolio

14.3.3.3 Finance

14.3.3.4 SWOT Analysis

14.3.4 Bristol-Myers Squibb Company

14.3.4.1 Company Overview

14.3.4.2 Product portfolio

14.3.4.3 Finance

14.3.4.4 SWOT Analysis

14.3.5 Eli Lilly and company

14.3.5.1 Company Overview

14.3.5.2 Product portfolio

14.3.5.3 Finance

14.3.5.4 SWOT Analysis

14.3.6 Emergent BioSolutions Inc.

14.3.6.1 Company Overview

14.3.6.2 Product portfolio

14.3.6.3 Finance

14.3.6.4 SWOT Analysis

14.3.7 F. Hoffmann-La Roche AG

14.3.7.1 Company Overview

14.3.7.2 Product portfolio

14.3.7.3 Finance

14.3.8 Gilead Sciences Inc.

14.3.8.1 Company Overview

14.3.8.2 Product portfolio

14.3.8.3 Finance

14.3.8.4 SWOT Analysis

14.3.9 GlaxoSmithKline plc

14.3.9.1 Company Overview

14.3.9.2 Product Portfolio

14.3.9.3 Finance

14.3.9.4 SWOT Analysis

14.3.10 Merck & Co. Inc.

14.3.10.1 Company Overview

14.3.10.2 Product Portfolio

14.3.10.3 Finance

14.3.10.4 SWOT Analysis

14.3.11 Novartis AG

14.3.11.1 Company Overview

14.3.11.2 Product portfolio

14.3.11.3 Finance

14.3.11.4 SWOT Analysis

14.3.12 Pfizer Inc.

14.3.12.1 Company Overview

14.3.12.2 Product Portfolio

14.3.12.3 Finance

14.3.12.4 SWOT Analysis

14.3.13 Sanofi SA

14.3.13.1 Company Overview

14.3.13.2 Product portfolio

14.3.13.3 Finance

14.3.13.4 SWOT Analysis

14.3.14 Takeda Pharmaceutical Company Limited

14.3.14.1 Company Overview

14.3.14.2 Product portfolio

14.3.14.3 Finance

14.3.14.4 SWOT Analysis

14.3.15 Viatris inc.

14.3.15.1 Company Overview

14.3.15.2 Product portfolio

14.3.15.3 Finance

For more information on this report, visit https://www.researchandmarkets.com/r/fm2u78

Media Contact:

Research and Markets

Laura Woodsenior

[email protected]

For EST office hours, call +1-917-300-0470

For USA/CAN call toll free +1-800-526-8630

For GMT office hours call +353-1-416-8900

US Fax: 646-607-1904

Fax (outside the US): +353-1-481-1716

Show original content:https://www.prnewswire.com/news-releases/insights-on-the-liver-disease-treatment-global-market-to-2027—by-treatment-type-disease-type-end-user- et-region-301523978.html

SOURCE Research and Markets